Drug Excipient Compatibility Study
Drug-excipient compatibility is a core prerequisite for pharmaceutical formulation development and commercial production, directly determining the stability, efficacy, safety and shelf life of drug products. Incompatible API-excipient combinations may trigger physical or chemical reactions—such as crystal form transformation, thermal degradation, moisture absorption aggregation, or functional group interaction—leading to reduced drug activity, increased impurities, or even product failure. As a leading pharmaceutical CRO, PharmaAnalytica offers a comprehensive, technology-driven Drug Excipient Compatibility Study service for Active Pharmaceutical Ingredients (APIs) and excipients, integrating cutting-edge thermal analysis, spectral analysis, diffraction analysis and microscopic characterization technologies. Our platform fully characterizes physical and chemical interactions between APIs and excipients, identifies potential incompatibility risks early, and provides scientific data support for rational excipient selection, formulation formula design and quality control, all in strict compliance with ICH, USP, EP and NMPA regulatory guidelines.
Centered on DSC, TGA, FTIR, PXRD, DVS, HSM, PLM and Raman Spectroscopy core technologies, our services cover the full dimension of API-excipient compatibility evaluation—from thermal stability and phase change behavior to molecular structure interaction, crystal form variation, moisture absorption characteristics and microscopic morphological changes. Each analytical technology is precisely tailored to detect specific compatibility risk points, forming a multi-technology complementary evaluation system to achieve accurate, comprehensive and systematic screening of API-excipient compatibility.
Specialized Drug Excipient Compatibility Study Services
Differential Scanning Calorimetry (DSC)
A core thermal analysis technology for evaluating thermal compatibility and phase change behavior of API-excipient mixtures. DSC measures heat flow changes during temperature programming to detect melting, crystallization, glass transition, thermal decomposition and exothermic/endothermic reactions between APIs and excipients, quickly identifying thermal-induced incompatibility risks (e.g., API thermal degradation catalyzed by excipients) and complying with USP <891> and EP 2.2.34 guidelines.
Thermogravimetric Analysis (TGA)
Specialized for thermal weight loss and decomposition compatibility analysis of API-excipient systems. TGA continuously measures sample weight changes with temperature/ time, quantifies moisture loss, volatile component evaporation and thermal decomposition kinetics of mixtures, and identifies compatibility risks such as accelerated API decomposition, excipient thermal degradation product interaction with APIs, and weight loss behavior changes of mixed systems, matching DSC for comprehensive thermal compatibility evaluation (USP <891>).
Fourier Transform Infrared Spectroscopy (FTIR)
A key molecular spectral technology for detecting chemical functional group interaction between APIs and excipients. FTIR analyzes the characteristic absorption peak changes of functional groups (e.g., hydroxyl, carboxyl, amino) in API-excipient mixtures compared with pure materials, identifies hydrogen bonding, esterification, complexation and other chemical interactions, and judges chemical incompatibility at the molecular level, providing a direct basis for screening excipients with no chemical reaction with APIs (USP <197ft>).
Powder X-ray Diffraction (PXRD)
The gold standard for evaluating crystal form compatibility and solid-state transformation of API-excipient systems. PXRD characterizes the crystal diffraction peak changes of mixtures, detects API crystal form conversion (e.g., amorphous to crystalline, polymorphic transformation), recrystallization, or amorphous formation induced by excipients, and identifies physical incompatibility risks such as reduced API solubility/bioavailability caused by crystal form changes, suitable for crystalline API-excipient compatibility screening (USP <941>).
Dynamic Vapor Sorption (DVS)
Specialized for moisture absorption/desorption compatibility analysis of API-excipient mixtures. DVS dynamically measures the moisture absorption isotherm and kinetic characteristics of samples under different humidity conditions, evaluates whether excipients cause accelerated API moisture absorption, hygroscopic aggregation or crystal water loss, and identifies moisture-induced compatibility risks, critical for the formulation design of hygroscopic APIs and excipients (USP <1174>).
Hot-Stage Microscopy (HSM)
A thermal microscopic technology for in-situ observation of thermal phase change compatibility of API-excipient mixtures. HSM combines optical microscopy with precise temperature control, in-situ observes morphological changes (e.g., melting, recrystallization, foaming, discoloration) of mixtures during heating/cooling, and correlates with DSC/TGA data to confirm thermal reaction types and temperature points, accurately identifying micro-scale thermal incompatibility phenomena that are difficult to detect by macro thermal analysis.
Polarized Light Microscopy (PLM)
A core microscopic technology for evaluating physical morphological and crystalline compatibility of API-excipient systems. PLM uses polarized light to observe the microscopic morphology, crystal shape and birefringence characteristics of mixtures, detects API particle agglomeration, crystal growth inhibition, or amorphous phase formation induced by excipients, and quickly screens physical incompatibility such as poor dispersion of API in excipients, suitable for preliminary compatibility screening of solid API-excipient mixtures (USP <776>).
Raman Spectroscopy
A complementary molecular spectral technology for in-situ, non-destructive compatibility analysis of API-excipient systems. Raman Spectroscopy analyzes the characteristic Raman peak changes of mixtures, identifies molecular structure interactions and solid-state changes between APIs and excipients, and has the advantages of non-destructive testing, little sample preparation and high sensitivity to crystal form/ molecular conformation changes. It is especially suitable for compatibility analysis of trace APIs, colored samples or samples that are difficult to characterize by FTIR (USP <197r>).
Why Choose PharmaAnalytica?
Multi-Technology Complementary System
8 core analytical technologies cover thermal, chemical, crystal, moisture and microscopic compatibility evaluation, achieving full-dimensional risk screening of API-excipient interactions.
Regulatory-Compliant Methodology
All test methods are validated in accordance with ICH Q2(R1), USP, EP and NMPA guidelines, with GLP-compliant raw data and detailed reports supporting formulation development and drug registration submissions.
Technology-Driven Accurate Evaluation
Advanced analytical instruments ensure high precision, repeatability and sensitivity of test results, and can detect subtle physical/chemical changes between APIs and excipients at an early stage.
Expert Data Interpretation
Our team of analytical scientists provides customized testing protocols, in-depth data interpretation, and actionable recommendations for API/excipient optimization and formulation development.
PharmaAnalytica's Drug Excipient Compatibility Study service takes advanced analytical technologies as the core, turns compatibility test data into actionable formulation design insights, and helps you rationally select excipients, avoid compatibility risks, and lay a solid scientific foundation for the development of stable, high-quality and compliant drug products.
Online Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Need More Information or Request A Quotation?
Related Links
